Guardant Health, Inc., a leading precision oncology company, is headquartered in the United States, with significant operations across North America and Europe. Founded in 2012, the company has rapidly established itself in the biotechnology industry, focusing on non-invasive cancer detection and monitoring through advanced genomic testing. Guardant Health is renowned for its flagship product, the Guardant360® test, which provides comprehensive genomic profiling of solid tumours using a simple blood draw. This innovative approach allows for personalised treatment strategies, setting the company apart in the competitive landscape of cancer diagnostics. With a strong market position, Guardant Health has achieved notable milestones, including partnerships with major pharmaceutical companies and contributions to pivotal clinical trials. Its commitment to transforming cancer care through cutting-edge technology continues to drive its success in the oncology sector.
How does Guardant Health's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Guardant Health's score of 32 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Guardant Health reported total carbon emissions of approximately 4,222,000 kg CO2e, comprising 1,659,000 kg CO2e from Scope 1 and 2,563,000 kg CO2e from Scope 2 emissions. The company has set ambitious near-term targets to significantly reduce its carbon footprint, aiming for near-zero emissions in both Scope 1 and Scope 2 by 2025. Additionally, Guardant Health is committed to a 30% reduction in Scope 1 and Scope 2 emissions from a 2023 baseline by 2030. These initiatives reflect the company's dedication to addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector, aligning with industry standards for sustainability and environmental responsibility.
Access structured emissions data, company-specific emission factors, and source documents
2023 | |
---|---|
Scope 1 | 1,659,000 |
Scope 2 | 2,563,000 |
Scope 3 | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Guardant Health is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.